91AV

Introduction

Small Molecule Protein Degraders: A New Opportunity for Drug Design and Development

This intensive course is intended for scientists working in the field, and the presentations will be given by senior scientists from industry and academia. The number of participants is limited to 35, to allow in depth discussion.

Course Outline

In the last ten years there have been significant developments in the field of designing small molecule protein degraders both as chemical tools and clinical candidates. These degraders can offer major advantages over small molecule inhibitors as a therapeutic strategy by achieving more complete target inhibition and by expanding the potentially druggable proteome. This course aims to provide opportunities for in depth discussions on the key aspects of PROTAC design and development for medicinal chemists. It will finish with a series of medicinal chemistry case studies, including the discovery of clinical small molecule protein degraders.

Deadlines

• Mar 10 2023
  Early bird registration deadline

  

Useful links

Speakers

• Dr Chun-wa Chung GlaxoSmithKline, United Kingdom
• Professor Alessio Ciulli University of Dundee, United Kingdom
• Dr Suzanne O'Connor University of Dundee, United Kingdom
• Dr Danette Daniels Foghorn Therapeutics, United States
• Dr Ingo Hartung Merck KGaA, Germany
• Dr Andrea Testa Amphista Therapeutics, United Kingdom

---

Venue

Castle Oud Poelgeest

Castle Oud Poelgeest, Poelgeesterweg 1, Oegstgeest, 2341 NM, Netherlands

Useful links

Committee

• Professor Alessio Ciulli University of Dundee, United Kingdom
• Dr Suzanne O'Connor University of Dundee, United Kingdom
• Professor Laura Heitman University of Leiden, Netherlands

---

Contact information

LD Organisation
Rue Michel de Ghelderode 33/02
BE B-1348 Louvain-la-Neuve
+32 (0)10 45 47 77
Contact us by email

---